fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

CHMP positive for treatment of plaque psoriasis with Cosentyx in children and adolescents aged 6 to <18 years.- Novartis

Written by | 27 Jun 2020

Novartis, announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx (secukinumab) for the treatment… read more.

Results from interim analysis of RESOLVE-IT phase III trial of elafibranor in adults with NASH and fibrosis. Genfit

Written by | 12 May 2020

Genfit announced results from an interim analysis of the RESOLVE-IT Phase III trial evaluating once-daily, 120mg of elafibranor in adults with non-alcoholic steatohepatitis (NASH). The trial did not… read more.

CHMP recommends Cosentyx for the treatment of adult patients with active non-radiographic axial spondyloarthritis. -Novartis

Written by | 29 Mar 2020

Novartis, announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx (secukinumab) for the treatment… read more.

World Health Matters: Germany: Concern over hepatitis B among refugees

Written by | 5 Sep 2016

by Gary Finnegan: People seeking refuge and asylum in Germany are at higher risks of liver problems due to hepatitis B, according to experts.

ILTS 2016: Professors John Lake (University of Minnesota, MN, USA) and John O’Grady (Kings College Hospital, London) discuss what’s novel in immuno-suppression. Also associated article included on Immunosuppression.

Written by | 13 Jun 2016

Biomarkers emerging as guide on immunosuppression by Thomas R. Collins Using the right amount of immunosuppression treatment, but no more than necessary, is a challenge facing clinicians handling… read more.

ILTS 2016: Professors John Lake (University of Minnesota, MN, USA) and John O’Grady (Kings College Hospital, London) discuss what's novel in immuno-suppression. Also associated article included on Immunosuppression.

Written by | 13 Jun 2016

Biomarkers emerging as guide on immunosuppression by Thomas R. Collins Using the right amount of immunosuppression treatment, but no more than necessary, is a challenge facing clinicians handling… read more.

ILTS 2014: Liver-directed cellular therapy – hope or hype?

Written by | 7 Aug 2014

Feature Symposium.  Stephen Strom, Karolinska Institutet, Stockholm, Sweden.   Luc van der Laan, Erasmus Medical Center, Rotterdam, the Netherlands.  Alberto Sanchez-Fueyo, King’s College Hospital, London, UK.  David Hay, University… read more.

ITLS 2014: Liver transplantation – aspiring to excellence: Current challenges and cutting edge developments

Written by | 6 Aug 2014

Report from the Joint International Congress of ILTS, ELITA and LICAGE 2014.   Recurrence of hepatitis C virus (HCV) infection after transplantation is a major challenge for centres all… read more.

ILTS 2014: State of the art lecture: Transplantation or medical care for acute liver failure

Written by | 6 Aug 2014

Report from the Joint International Congress of ILTS, ELITA and LICAGE 2014.  Roger Williams, Institute of Hepatology/Foundation for Liver Research, London, UK.   Medical care after acute liver failure… read more.

ESOT 2013 Report – Retransplantation of abdominal organs

Written by | 23 Oct 2013

Re-transplantation is the only option available for salvaging a failed abdominal graft. As the outcomes after primary transplantations continue to improve, even with the increasing use of extended-criteria… read more.

EASL 2013 Report – Hepatitis C treatment in rapid transition

Written by | 4 Jun 2013

by Bruce Sylvester – Nine thousand clinicians gathered at the 2013 annual meeting of the European Association for the Study of the Liver/International Liver Congress in Amsterdam on… read more.

EASL 2013 Report – MK-5172 shows high, durable response in HCV

Written by | 30 May 2013

Hepatitis C patients treated with Merck’s investigative MK-5172, an oral NS3/4A protease inhibitor, combined with 24 or 48 weeks of peginterferon alfa 2b (Pegasys/ Roche) and ribavirin (Ribasphere/… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.